Improvement of the efficacy and safety of treatment of epilepsy using new forms of controlled release antiepileptic drugs

Ermolenko N.A.; Buchneva I.A.

doi:https://doi.org/10.17116/jnevro20181186183

Close metadata

Recommended articles:

Febrile infection-related epilepsy syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):34-40

The potential of cortical electrical stimulation for the study of autonomic dysfunction in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):25-34

The role of neuroinflammation in the development of seizure activity and autonomic disorders in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):50-58

Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cerebrovascular accidents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31

Therapies for focal epilepsy associated with brain tumors. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):14-20

The relationship between the interictal parameters of cardiovascular autonomic regulation and the outcomes of surgical treatment of epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):50-59

Factors and features of the development of epilepsy in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):18-27

Type 28 spinocerebellar ataxia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):61-64

Evolution of DEE-SWAS into photosensitive epilepsy in a patient with an ASH1L gene mutation. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):114-119

A personalized approach to the diagnosis of epilepsy in obese children. Laboratory Service. 2025;(1):5-12

Abstract:

The paper summarizes the results of the studies on the efficacy and safety of a new form of controlled release levetiracetam XR (Lev XR) compared to standard tablet immediate release form in treatment of resistant partial seizures. The authors present the data on the bioequivalence and absorption of LevXR related to the meal and therapeutic doses in the range between 1000 to 3000 mg/day. It has been concluded that LevXR has high efficacy and safety due to its stable plasma concentration during the day. The results meet FDA bioequivalence criteria and, in authors opinion, can be recommended as drug of choice in additional treatment of partial seizures in patients above 12 years of age.

Keywords:

antiepileptic drugs

epilepsy

controlled release levetiracetam

bioequivalence

Authors:

Ermolenko N.A.

Voronezhskaia gosudarstvennaia meditsinskaia akademiia im. N.N. Burdenko

Buchneva I.A.

Voronezhskaia oblastnaia detskaia klinicheskaia bol'nitsa #1

Close metadata

References:

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, MoshÃ© SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. https://doi.org/10.1111/epi.12550
Covanis A, Guekht A, Li S, Secco M, Shakir R, Perucca E. From global campaign to global commitment: The World Health Assemblyâ€™s Resolution on epilepsy. Epilepsia. 2015;56:11:1651-1657. https://doi.org/10.1111/epi.13192 The link is active on: 27.03.2017. (In Russ.) http://www.who.int/mediacentre/factsheets/fs999/ru/
Statistical materials. Ministry of Health of the Russian Federation, 2015. The link is active on: 27.03.2017. (In Russ.) https://www.rosminzdrav.ru/
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, MoshÃ© SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. A practical clinical definition of epilepsy. Epilepsia. 2014;55:475-482.
Karlov VA. Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin. Rukovodstvo dlya vrachei. M.: Meditsina; 2010. (In Russ.)
Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008;71:1572-1578. https://doi.org/10.1212/01.wnl.0000319693.10338.b9
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319. https://doi.org/10.1056/nejm200002033420503
Gekht AB. Epidemiology and economic aspects of epilepsy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2005;105:8:63-65. (In Russ.)
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83:1-43. https://doi.org/10.1016/j.eplepsyres.2008.09.005
Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor JrSR, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: Predictors and comparison of all commonly used antiepileptic drugs. Epilepsy & Behavior. 2009;14:202-209. https://doi.org/10.1016/j.yebeh.2008.10.017
Gilliam F. Epilepsy â€” success in clinical practice: translating trials to practice. European Journal of Neurology. 2005;12(4):22-29. https://doi.org/10.1111/j.1468-1331.2005.01328.x
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277. https://doi.org/10.1001/jama.1989.03420220087032
Karlov VA. Pharmacoresistance and tolerability in epilepsy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108:10:75-80. (In Russ.)
Stephen J, Brodie M.J. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin. 2012;25(2):164-172.
Burd SG. Effect of drug formulation on the treatment of epilepsy. Epilepsiya i Paroksizmal’nye Sostoyaniya. 2013;5:2. (In Russ.)
Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partialonset seizures. Epilepsia. 2007;48:497-504. https://doi.org/10.1111/j.1528-1167.2007.00984.x
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:410-423. https://doi.org/10.1111/j.0013-9580.2004.06304.x
Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs. 2007;21:765-774. https://doi.org/10.2165/00023210-200721090-00005
Sommerville KW. Bioequivalence in development of antiepileptic drugs. Epilepsy Res. 2006;68:82-85. https://doi.org/10.1016/j.eplepsyres.2005.09.033
Verrotti A, Salladini C, Di Marco G, Pisciella F, Chiarell, F. Extended-release formulations in epilepsy. J Child Neurol. 22:419-426. https://doi.org/10.1177/0883073807302760
Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Epiterra. Registratsionnoe udostoverenie: LP-002104. The link is active on: 13.04.2018. (In Russ.) http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=000acf9d-89bb-4178-b15e-ea3b2d284a98&t=c3ff4882-4813-4397-9396-1f94bcf36438
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Epilepsia. 2004;26(26):9861-9866. https://doi.org/10.1073/pnas.0308208101
Karlov VA, Vlasov PN, Zhidkova IA. Efficacy of generic levetiracetam (epiterra) in monotherapy for epilepsy in adult patients: preliminary results. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2015;(spetsvypusk 1):36-40. (In Russ.)
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A., Guerreiro C., Kälviäinen R., Mattson R., French J.A., Perucca E., Tomson T., for the ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563. Epub 2013 Jan 25. https://doi.org/10.1111/epi.12074
Peltola J, Coetzee C, Jimenez F, Litovchenko T, Ramaratnam S, Zaslavskiy L, Lu Z, Sykes DM, on behalf of the Levetiracetam XR N01235 Study Group, 2008. Once-Daily Extended-Release Levetiracetam as Add-On Therapy in Patients with Refractory Partial-Onset Seizures: Double Blind, Placebo-Controlled Trial. Epilepsia. October 14 [Epub ahead of print]. https://doi.org/10.1111/j.1528-1167.2008.01817.x
Rouits E, Burton I, Guénolé E, Troenaru MM, Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam XR 500mg tablets. Epilepsy Res. 2009;84(2-3):224-231. Epub 2009 Mar 4. https://doi.org/10.1016/j.eplepsyres.2009.02.001
Richy FF , Banerjee S, Brabant Y, Helmers S. Levetiracetam extended release and levetiracetam immediate release asadjunctive treatment for partial-onset seizures: An indirect comparison of treatment-emergent adverse events using meta-analytic techniques. Epilepsy & Behavior. 2009;16:240-245. https://doi.org/10.1016/j.yebeh.2009.07.013
Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf. 2004;3:415-442. https://doi.org/10.1517/14740338.3.5.415
Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-724. https://doi.org/10.2165/00003088-200443110-00002
Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of the fundamentals. J Clin Pharmacol. 2002;42:620-643. https://doi.org/10.1177/00970002042006005
Belousov YuB, Gurevich KG. Klinicheskaya farmakokinetika. Praktika dozirovaniya lekarstv. M.: Litterra; 2005. (In Russ.)
Otsenka bioekvivalentnosti lekarstvennykh sredstv. Metodicheskie ukazaniya. Ministerstvo zdravookhraneniya i sotsial’nogo razvitiya RF, Federal’naya sluzhba po nadzoru v sfere zdravookhraneniya i sotsial’nogo razvitiya, FGU «Nauchnyi tsentr ekspertizy sredstv meditsinskogo primeneniya». M. 2008. (In Russ.)
Jiang W, Makhlouf F, Schuirmann DJ, Zhang X, Zheng N, Conner D, Yu LX, Lionberger R. A bioequivalence approach for generic narrow therapeutic index drugs: evaluation of the reference-scaled approach and variability comparison criterion. The AAPS Journal. 2015;17:4:891-901. https://doi.org/10.1208/s12248-015-9753-5
Health Canada. Comparative bioavailability standards: formulations used for systemic effects. Accessed in December 2013. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normes-eng.pdf. 2012
European Medicines Agency. Questions & answers: positions on specific questions addressed to the pharmacokinetics working party. Accessed in December 2013. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pd
Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann DJ, Muldowney L, Chen ML, Davit B, Conner D, Woodcock J. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286-291. Epub 2014 Dec 15.PMID:25669762. https://doi.org/10.1002/cpt.28 http://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm The link is active on 13.04.2018.